Statement of Significance: Bacteria residing within the human body have been shown to influence 1 human health. It is likely that physiological responses to the human microbiota are mediated by the 2 collection of small molecules encoded within these bacteria. In this study we use direct functional 3 screening of small molecules produced by individual members of a simplified human microbiota to identify 4 new G protein coupled receptor-metabolite interactions that seek to explain the molecular underpinnings 5 of the microbiota's influence on its human host. 6 7
Human bodies are home to diverse and ever-changing collections of bacteria. The ability of the microbiota 1 to influence human health has been explored extensively.
[1] The most common methods for studying 2 host-microbe interactions have featured "omics" based-analyses that have examined genomic, 3 transcriptomic, proteomic or metabolic differences between patient cohorts. [2] [3] [4] [5] Although these 4 informatics-based methods have served as powerful tools for uncovering correlations between changes 5 in the microbiota and health and disease, they are somewhat limited in their ability to reveal the 6 mechanistic details of how the microbiota might alter mammalian physiology.
[6] Much of the influence 7 the microbiota has on its human host is likely encoded in the collection of small molecules it produces or 8 modulates. [7] However, the number of well-defined interactions between metabolites produced by human 9 associated bacteria and discrete human receptors is dwarfed by the number of reports attributing 10 biological phenotypes to the microbiome, highlighting the need for a more systematic characterization of 11 microbiota encoded bioactive metabolites. 12 13
In the case of synthetic small molecules that have proved useful for therapeutically modulating human 14 physiology (i.e., U.S. Food and Drug Administration (FDA) approved drugs) the majority (60-70%) 15 function through just three classes of receptors: G-protein coupled receptors (GPCR), ion channels, or 16 nuclear hormone receptors.
[8] Many of these same proteins bind endogenous signaling molecules that 17 regulate a wide range of physiological responses.
[9] Based on the fact that these receptors play such an 18 important role in how eukaryotic cells have evolved to translate external chemicals into biologic 19 responses, it is likely the microbiota affects host physiology by modulating these same receptors with 20 secreted metabolites. 21 22
Although healthy humans are colonized by hundreds, if not thousands of different bacterial species, the 23 metabolic diversity they generate is likely limited by a high level of biosynthetic redundancy between 24 bacterial species.
[10] Due at least in part to this metabolic redundancy, it has been possible to use 25 simplified human microbiomes (SIHUMIs) to model health and disease in murine models. [11, 12] In lieu 26 of exploring random individual commensal species, we sought to conduct a more in-depth investigation 27 of GPCR active microbiota encoded metabolites using bacteria from a model SIHUMI that contained a 28 taxonomically diverse collection of commensal, health promoting and pathogenic bacteria. This 29 consortium, which is composed of seven bacteria, assembled as a tool for studying gastrointestinal 30 inflammation in the context of a healthy bacterial flora fulfills these general criteria and was therefore 31 selected for use in this study.
[13] Bacteria present in the SIHUMI consortium represent the major taxa 32 found in the human microbiome and include beneficial bacteria (Lactobacillus plantarum, Bifidobacterium 33 longum, and Faecalibacterium prauznitzii), non-pathogenic bacteria associated with disease 34 (Bacteroides vulgatus and Ruminococcus gnavus), as well as clinically relevant pathogens (Escherichia 35 coli LF-82 and Enterococcus faecalis). 36 37
We screened the metabolites produced by individually grown members of this SIHUMI consortium for 38 agonism against 241 GPCRs. The resulting interaction map provides evidence, at the molecular level, 39
for the existence of a complex network of microbial-host interactions, many of which involve receptors 40 that have been modulated therapeutically with synthetic small molecules. Our characterization of 41 interactions predicted by this analysis led to the discovery of both previously unrecognized as well as 42 known microbiota encoded GPCR agonists. Bacteria from the SIHUMI consortium were individually fermented under anaerobic conditions in separate 49 large scale (20L) culture vessels ( Figure 1 ). After 10 days of static fermentation at 37 °C, hydrophobic 50 resin was added directly to each culture. The resulting suspension was mixed to allow organic metabolites 51 present in the fermentation broth to bind to the absorbent resin. Metabolite loaded resin was then 52 collected by filtration, washed, and the bound metabolites were eluted with acetone. Each resulting crude 1 metabolite extract was partitioned into 9 metabolite-rich fractions using reversed phased flash 2 chromatography. A small aliquot of each fraction was arrayed for use in high-throughput GPCR 3 screening. The remaining material was saved for follow up assays and for use in molecule isolation and 4 structure elucidation studies. Although this pre-fractionation process increases the number of samples to 5 be screened it simplifies the complexity of the crude culture broth extracts, which improves the signal in 6 the primary screen thereby increasing the diversity of interactions that are identified and facilitating the 7 downstream isolation of bioactive compounds. In addition to the bacterial fermentations, media not 8 inoculated with bacteria was processed under identical conditions to control for possible bioactivity of 9 small molecules derived directly from the media. The resulting library of bacterial metabolites was then 10 screened with a cell-based assay for fractions that could agonize members of a panel of 241 GPCRs 11 (Table S1 ). Specifically, a collection of recombinant cell lines engineered to measure β-arrestin 12 recruitment by individual GPCR targets (β-arrestin recruitment assay) was used. For GPCRs with well 13 characterized endogenous ligands, a maximum value for β-arrestin recruitment (100%) was set by 14 exposing the recombinant cell line to a known agonist (Table S1 ). In the case of orphan receptors (i.e., 15 receptors without well characterized endogenous ligands), normalization of β-arrestin recruitment was 16 performed by assigning the vehicle control to 0% activity. Hits were classified as such if a fraction induced 17 a GPCR response to >30% of the control ligand (>50% for orphan GPCRs) and the comparable media 18 control fraction showed <30% activity against the same GPCR (<50% for orphan GPCRs). 19 20
The bacterial fraction library induced β-arrestin recruitment above our hit threshold levels for 67 of the 21 241 individual GPCR reporter cell lines we tested ( Figure 2A -B, Table S2-S3). Of these 67 GPCRs, 54  22 did not show a strong background signal from the corresponding media control fraction, suggesting they 23 were responding to bacterially encoded metabolites. Manual review of these 54 hits led us to de-prioritize 24 15 of these GPCR-fraction pairs due to high background of either the receptor or fraction (Table S4 ). The 25 remaining 39 GPCRs were re-assayed in replicate; 22 of these GPCRs showed reproducible β-arrestin 26 recruitment in response to 1 or more bacterial fractions ( Figure 2C ). Based on data from the Human 27
Protein Atlas most of the receptors that reproducibly responded to bacterial metabolites are expressed 28 at body sites regularly exposed to the microbiota ( Figure 2C ). [14] Notably, a large number of the receptors 29 that were reproducibly agonized by microbiota encoded metabolites are also targeted by FDA approved 30 drugs, indicating that receptors with proven physiological relevance are potentially modulated by bacterial 31 ligands ( Figure 2C ). To identify specific GPCR-active metabolites, we used bioassay-guided isolation to 32 purify metabolites from the large-scale culture broth fractions and de novo structure elucidation methods 33 to determine their structures. 34 35
Known and novel ligands for hydroxycarboxylic acid receptors: 36 A number of receptors agonized in our screen are known to respond to bacterial ligands. As an initial 37 validation exercise we characterized activities expected to arise from well-known bacterial GPCR 38 agonists. The hydroxycarboxylic acid receptors, GPR81, GPR109A and GPR109B, are agonized by both 39 human and bacterial ligands.
[15] Bioassay guided fractionation of GPR109A active fractions from 40 cultures of both L. plantarum and R. gnavus yielded nicotinic acid (Vitamin B3) as the active metabolite 41 ( Figure 3A , Figure S1 ). Nicotinic acid, an essential nutrient acquired either through diet or gut bacteria, 42 is the most extensively studied non-endogenous ligand for this receptor. Its ability to regulate lipid 43 metabolism in hyperlipidemic patients is well established in the clinic.
[16] The identification of this well 44 characterized and in vivo validated ligand receptor pair suggests that data generated in our screen has 45 the potential to uncover new biologically relevant metabolite GPCR interactions. 46 47
Fractions derived from cultures of both E. coli LF82 and L. plantarum agonized a second 48 hydroxycarboxylic acid receptor, GPR109B. Bioassay guided fractionation did not identify the 49 endogenous ligand produced in humans, 3-hydroxyoctanoic acid, but instead yielded phenylpropanoic 50 acid as the active metabolite ( Figure 3B , Figure S1 ). This previously unknown GPR109B agonist, elicited 51 a similar GPCR response than did 3-hydroxyoctanoic acid ( Figure 3B ). While the EC50 values for the 52 known and novel ligands (304 μM and 208 μM, respectively) are higher than is often seen for endogenous 1 GPCR ligands (Table S1) Figure 3C ). Isolation of the active metabolite yielded 23 tryptamine, which was produced in varying quantities by members of this SIHUMI ( Figure S3 ). These 24 results agree with various reports that HTRs are responsive to a wide array of bacteria due to the 25 generality of tryptamine production across species.
[26] 26 27
In fractions from multiple bacterial species we observed agonism of the D2-type dopamine receptors 28 (DRDs), DRD2 and DRD3 ( Figure 3D ). Bioassay-guided isolation led to the aromatic amine tyramine as 29 the major metabolite responsible for DRD agonism in these fractions. Tyramine arises from 30 decarboxylation of tyrosine and differs from dopamine only by the absence of a second hydroxyl on the 31 aromatic ring. It is reported to accumulate to μM levels in the gastrointestinal tract, a phenomenon which 32 has been attributed to production by human microbiota.
[27] While no biological significance has been 33 assigned to the microbiota dependent accumulation of tyramine in animal models, it is sufficiently potent 34 that its observed concentration in the gastrointestinal tract is high enough to agonize D2 subtype DRDs. 35 36
In contrast to the broad activation seen for DRDs and HTRs across extracts from all of the bacteria in 37 this consortium, a specific response to fractions from E. coli LF82 was detected for a member of the 38 histamine receptor (HRH) family, HRH4. Our inability to retain HRH4-activity when using hydrophobic 39 chromatography during the bioassay guided purification process suggested that the active molecule was 40 highly polar. We did not, however, expect that the activity was due to bacterially produced histamine, as 41 the active fraction did not agonize other HRH family receptors and we could not detect histamine by LC-42 MS or NMR. We ultimately found the polyamine cadaverine to be the metabolite responsible for HRH4 43 agonism ( Figure 4A ). The activity of cadaverine was confirmed using a commercial standard (EC50 1.1 44 μM) ( Figure 4B ). In addition to cadaverine, bacteria commonly produce a number of other simple 45 polyamines including agmatine, spermidine and putrescine.
[28] To explore the promiscuity of HRH4 46
agonism by polyamines, we tested synthetic standards of these metabolites for the ability to induce β-47 arrestin recruitment by each member of the HRH receptor family. Agmatine and putrescine showed 48 limited activity against HRH4 ( Figure 4C ), while spermidine did not show activity against any receptor in 49 the family. The inability for humans to biosynthesize cadaverine suggests that the influence of polyamines 50 on histamine signaling pathways is likely specific to bacterial metabolism. 51 52
Cadaverine is produced by bacteria through the decarboxylation of lysine ( Figure 4A ), while agmatine 1 and putrescine are derived from arginine. In a number of bacteria, including many associated with the 2 microbiota (Table S5) Figure 5A ). Based on the receptor interaction map we could initially classify 23
GPCRs as lipid responsive if they were agonized by the late lipid-enriched fractions of the extract library. 24
A subset of receptors, including GPR120, CNR2, GPR171, GPR132, responded broadly to the lipid 25 fraction from most of the consortium, whereas other responses were specific to particular species (BAI1, 26 NMU1R, UTR2). HPLC-charged aerosol detection analysis of the lipid fractions indicated they contained 27 not only mixtures of simple saturated fatty acids but also other more complex lipid species ( Figure 5B ). 28
Marrying unique receptor activity profiles with unique lipid signals guided us to previously unrecognized 29 bacteria encoded GPCR agonists. 30 31
The brain angiogenesis factor 1 (BAI1) receptor was agonized by lipid fractions from the Gram-negative 32 bacteria in the consortium: E. coli and B. vulgatus. The E. coli LF82 lipid fraction showed the most potent 33 agonism of BAI1 and therefore it was selected for further analysis. Bioassay guided fractionation 34 identified the BAI1 agonist as the cyclopropyl-containing lipid 9,10-methylenehexadecanoic acid (EC50 35 11 μM). Synthetic 9,10-methylenehexadecanoic acid, but no saturated lipids we tested agonized BAI1, 36 confirming the specificity of the receptor reflected in the initial GPCR activity map ( Figure 5C ). The 37 enzyme cyclopropane-fatty-acyl-phospholipid synthase (Cfa) uses the one carbon donor S-adenosyl-L-38 methionine to generate cyclopropyl lipids from unsaturated fatty acids ( Figure 5G ). Two peptide receptors NMU1R (neuromedin receptor 1), which mediates satiety and peristalsis in the 45 gut [43, 44] and the vasoconstriction inducing urotensin 2 receptor (UTR2) responded specifically to lipid 46 fractions generated from B. vulgatus. Isolation of the active metabolite yielded the anteiso-methyl 47 branched-chain fatty acid 12-methyltetradecanoic acid (aiC15:0) ( Figure 5D ). Anteiso-fatty acids (ai) 48 contain an alkyl branch at the ante-penultimate carbon in contrast to iso-fatty acids (i) which branch at 49 the penultimate carbon. Both synthetic and natural aiC15:0, but no simple fatty acids we tested, agonized 50 NMU1R (EC50 125 μM) and UTR2 (EC50 191 μM). Lipid sensitivity of NMU1R and UTR2 appears specific 51 to aiC15:0, as fatty acids with even slightly modified branching patterns (iC15:0) or carbon chain length 52 (aiC17:0) displayed minimal agonist activity ( Figure 5E -F). Methyl branched fatty acids arise from the use 1 of a branched primer in place of acetyl CoA in normal fatty acid biosynthesis. In the case of anteiso-2 methyl-branched fatty acids, 2-methyl-butyryl-CoA, which is derived from isoleucine is used to prime fatty 3 acid biosynthesis ( Figure 5G ). In parallel with our in vitro screen studies, we used high-resolution mass spectrometry-based 20 metabolomics to compare germ free and SIHUMI consortium colonized mice. For this analysis, cultures 21 of individually grown bacteria from the consortium were combined and the mixed sample was gavaged 22 into germ-free C57BL/6 mice. PCR based species analysis of DNA extracted from the stool of animals 23 three days post inoculation confirmed their colonization by the consortium. Ten days post colonization 24 the lumen material (cecal stool) was collected from the germ-free controls as well as the SIHUMI 25 colonized animals. Using targeted high-resolution mass spectrometry, we looked for differences in 26 metabolite accumulation in these samples ( Figure 6 ). 27 28
Targeted MS analysis of cecum extracts revealed that all but one of the GPCR-active metabolites we 29 identified was enriched in these mice compared to their abiotic counterparts ( Figure 6 , Table S7),  30 suggesting a largely parallel biosynthesis in laboratory grown mono-cultures and the consortium in vivo. 31
The lone exception was phenylpropanoic acid. Our failure to identify phenylpropanoic acid in this specific 32 model study does not preclude its potential biologic relevance in other settings, especially in light of the 33 fact that it has been seen at μM levels in human patient samples.
[18] The lack of in vivo production is 34 likely due to low production of this metabolite by the specific strain used in this consortium, which is 35 supported by the low GPR109B activity we observed in our original fraction screen. indicating -arrestin recruitment response normalized to endogenous or synthetic control compound 5 (100%). B) GPCR hit prioritization scheme. C) Subset of GPCRs that show <30% (50% for orphans) 6 response to the media control, but have >30% response (50% for orphans) to a bacterial fraction. The 7 orphan receptors in this pool are BAI1, GPR146, GPR151 and OPN5. Receptor gene expression levels 8 in tissues commonly exposed to the human microbiome (TPM, transcripts per million). Data is from the 9 Human Protein Atlas. Structure of NMU1R-active lipid, 12-methyltetradecanoic acid, isolated from B. vulgatus and response of 7 NMU1R GPCR to various fatty acids. E) Panel of branched chain fatty acids tested for GPCR fidelity. F) 8
Response of NMU1R, UTR2 (specific) and GPR120 (general) to branched chain fatty acid panel. G) 9
Biosynthesis of cyclopropane rings from unsaturated fatty acids using cyclopropane fatty acid synthase 10 (CFA). H) Early steps in the biosynthetic scheme for ante-iso branched chain fatty acids (BCFAs) in 11 bacteria (BKD, branched-chain -keto acid dehydrogenase; FabH, β-ketoacyl-acyl carrier protein 12 synthase III). All dose-response curves were run in duplicate. Error bars are standard deviation. Error 13 bars that are shorter than height of the symbol are not shown. 14 15 1 2 3 Figure 6 . Comparative analysis of metabolite levels in the cecum of abiotic mice to levels in mice 4 inoculated with SIHUMI consortium. Metabolite presence in lumen cecal samples was determined by 5 high-resolution mass spectrometry (see Methods for experimental details). Samples were normalized to 6 each other based on the addition of isotopically labeled internal standards during extraction, n=6 mice (3 7 female and 3 male), error bars are standard deviation, p values are derived from the unpaired t test. g/L maltose, 1 g/L cellobiose, and 0.5g/L L-cysteine), which can be made ahead of time and 6 stored, protected from light, at -20 °C in aliquots, except hemin which can be stored at 4 °C and 7 L-cysteine which should be made fresh. Use autoclaved deionized water to bring final volume to 8 1 L. For culturing anaerobes: place media in anaerobic chambers for at least 48 hrs to allow 9 diffusion with anaerobic gas. 10 11
Cultivation of bacteria: Bacterial strains of the SIHUMI consortium used listed in Table S2 . 12
Cultures of <1 L: Anaerobic bacteria were cultured in an incubator set to 37 °C placed inside of 13 vinyl anaerobic chamber (Coy) with a gas mix of 5% CO2, 5% H2, and 90% N2. used: Bacterial stocks were thawed and used to inoculate 5 mL LBM liquid cultures that were 36 cultivated overnight. The next day, species specific primers were used to confirm identity (as 37 described below) and upon passing purity check, these 5 mL cultures were used to inoculate 500 38 mL LBM at a ~1:100 ratio. After turbidity was reached, an aliquot of the 500 mL culture was 39 removed and PCR was performed with universal 16s rRNA primers 27F 40 (AGAGTTTGATCMTGGCTCAG) and 1492R (GGTTACCTTGTTACGACTT). The CR product 41 was subject to Sanger sequencing (GeneWiz) and upon passing inspection for the correct 42 species, the 500 mL culture was used to inoculate 12 L of LBM media at a 1:100 inoculation ratio. 43
The 20 L cultures were cultivated, protected from light at 37 °C, for 10 days without shaking. 44
Amerlite XAD-7HP (Sigma Aldrich) was aliquoted in 20 g increments and activated by soaking in 45 methanol for 10 minutes, followed by 5 washes with deionized water to remove excess methanol. 46
After 10 days, activated Amberlite XAD-7HP was added to the cultures (20 g dry weight/L) and 47 the slurries were gently shaken (90 rpm) on a tabletop shaker for 4 hrs. After incubation with the 48 cultures, the resin was removed via cheese-cloth filtration and the collected resin. alongside the 49 cheese-cloth, was placed inside a 1 L Fernbach flask to which 1.5 L acetone was added. This 50 acetone elution was allowed to occur for 2 hrs with shaking (150 rpm), after which the organic 1 solvent was collected and fresh acetone, of equivalent volume, was added. This second elution 2 was allowed to occur overnight with light shaking at 22 °C. Both elutions were added together and 3 solvent was removed via rotary evaporation (Buchi) at 25 °C to afford the dry crude extract, which 4 was stored at -20 °C until fractionated, as detailed below. 5 6
Fractionation of bacterial extracts: Crude extracts (~1-3 g/12L) were re-suspended in ~300 mL 7 methanol and the soluble material was decanted into a 500 mL round bottom flask (rbf). Free C18 8 resin (2-3 g) was added and the slurry was evaporated under reduced pressure using a rotary 9 evaporator with temperature set to 25 °C (Buchi). The dry material was collected from the rbf, 10 packed semi-tightly into a 50 g cartridge, and capped with a passive frit (Teledyne). This material 11 was chromatographed over a 150 g C18 Gold (Teledyne ISCO) using a solvent system of water 12 (Solvent A) and methanol (Solvent B), with no acid added, with the following conditions. 5 column 13 volumes (CV) of 5% B, 5% B to 99% B over 10 CV, flush with 10 CV 99% B. All flow-through was 14 collected in 50 mL tubes and combined as follows: 15 16 Solvent was evaporated using an SPD-2010 speedvac (Thermo Scientific) with a RH-19 rotor 17 (Thermo Scientific) and the resulting dry material was weighed and resuspended at 100 mg/mL 18 using ACS grade DMSO (Fisher Scientific). Of this solution, 250 µL was removed and added to 19 250 µL DMSO to create 500 µL 50 mg/mL solution; this solution was aliquoted into various sizes 20 of 96-well plates for facile thawing and biological testing at a later time. The remaining 100 mg/mL 21 solution was stored at -80 °C until validation studies required material for bio-assay guided 22 fractionation. 23 24 GPCR assays 25 GPCR activities were measured by Eurofins DiscoverX using the PathHunter® β-Arrestin 26 assay.
[1] This assay uses β-galactosidase (β-Gal) that has been split into two inactive portions 27 as a reporter to measure the activation of a GPCR. The β-Gal fragments are called EA for Enzyme 28
Acceptor and ED for Enzyme Donor.(US Patent: US20090098588A1). Using these fragments, a 29 unique reported cell line was created for each GPCR of interest. In each unique cell line the EA 30 fragment is fused to β-Arrestin and the ED fragment is fused to the GPCR of interest. Upon GPCR 31 activation, β-Arrestin recruitment to the receptor physically colocalizes the ED and EA fragments 32 thereby restoring β-Gal activity. β-Gal complementation is measured using chemiluminescent 33 PathHunter® Detection Reagents. For our initial screen (Figure 2 ) all 80 culture broth extract 34 fractions were screened in singleton against the Eurofins DiscoverX gpcrMAX (168 GPCRs, Table  35 S2) and orphanMAX (73 GPCRs, Table S3 ) panels. All subsequent validation and bioassay 36 guided fraction studies were run in at least duplicate using individual reporter cell lines for specific 37
GPCRs of interest. 38 39
Eurofins DiscoverX generic agonist protocol: 40 1. Sample is added to individual GPCR reporter cell lines grown in microtiter plates. Cells are 41 incubated at 37 °C or room temperature for 90 or 180 minutes. 2. Assay signal is generated 42 through addition of 12.5 or 15 μL (50% v/v) of PathHunter Detection reagent cocktail, followed by 43 incubation for a one hour at room temperature. 3. Microplates are read with a PerkinElmer 44
EnvisionTM instrument for chemiluminescent signal detection. 4. Compound activity is analyzed 45 using the CBIS data analysis suite (ChemInnovation, CA). For receptors with known ligands, 46 percentage activity is calculated using the following formula: % Activity =100% x (mean RLU of 47 test sample -mean RLU of vehicle control) / (mean MAX control ligand -mean RLU of vehicle 48 control). For orphan receptors, percentage inhibition is calculated using the following simplified 49 formula: % Activity =100% x (mean RLU of test sample -mean RLU of vehicle control) / (mean 50 RLU of vehicle control). For some orphan receptors that exhibit low basal signal, the more 1 sensitive PathHunter Flash Kit is used. 2 3
Cadaverine biosynthesis bioinformatics 4
Using the annotated genome of E. coli LF-82 the Pfam protein features of CadA (Accession ID 5 LF82_0254) or the amino acid sequence itself were used as a query against the annotated 6 genome collection provided by the NIH Human Microbiome Project. [2, 3] This dataset was chosen 7
as it allowed us to confidently assign annotated bacterial genomes containing a cadA gene to 8 body sites origin. For the Pfam analysis: three Pfam motifs are found within the CadA amino acid 9 sequence: PF01276 constitutes the major domain of the decarboxylase, PF03711 constitutes the 10 C-terminal domain and PF03709 constitutes the N-terminal domain. The raw data for both BlastP 11 (>30% identity) and Pfam-based analyses are available in Table S5a and S5b, respectively. 12 13
High-Resolution Mass Spectrometry of purified compounds 14 High Resolution Mass Spectrometry was acquired on a C18 column (Thermo Acclaim 120 C18, 15 2.1 x 150 mM) using a Dionex U-3000 HPLC system connected to an LTQ-Orbitrap Mass 16
Spectrometer (Thermo-Fisher). 17 18
Murine work 19
All experimental procedures were approved by the Animal Care and Use Committee of The Icahn 20
School of Medicine at Mount Sinai (PI Cohen IACUC-2016-0491). Germ free C57BL/6 mice were 21 maintained in sterile isolators with autoclaved food and water in the Gnotobiotic Facility of the 22
Faith Lab at Mount Sinai. 6-week-old mice were used for all experiments (3M and 3F in the 23 treatment group, 5M and 1F in the control group). The treatment group was colonized with the 24 SIHUMI whereas the control group was left germ free. For colonization studies 5 ml of an 25 overnight culture in LBM media of the SIHUMI (treatment group) was centrifuged at 500 x g for 2 26 minutes, the supernatant was decanted and the cells were resuspended in 2 ml of sterile PBS. 27
Germ free mice were gavaged with 100 µL of bacterial culture immediately upon removal from 28 sterile isolators. Colonization was confirmed by collection of fecal pellets after 3 days. Crude DNA 29 was extracted from fecal pellets per protocol (ZymoBIOMICS DNA/RNA Miniprep Kit) and 30 colonization conformed by targeted PCR of each strain using specific primers as detailed above. 31
After colonization mice were housed in specific-pathogen-free conditions and fed with autoclaved 32 water and food. After colonization for 7 days the mice were euthanized and samples were 33 collected for analysis. 200 mg of cecal contents were collected from each mouse and placed 34 immediately at -80 °C. The animal experiments were not randomized and the investigators were 35 not blinded to the allocation during experiments and outcome assessment. No statistical methods 36 were used to predetermine sample size. All mice which completed the experiments were 37 analyzed. 38 39
Metabolite quantitation by mass spectrometry 40 Cecal samples were weighed into 2 mL microtubes containing 2.8 mm ceramic beads (Omni 41 International) and resuspended to a final concentration of 100 mg/mL using 80:20 methanol:water 42 containing phenol-d7, palmitic acid-d31 and Method 1: GC-nCI-MS with PFB Derivatization. 100 µL of cecal extract was added to 100 µL 48 of 100 mM borate Buffer (pH 10), 400 µL of 100 mM pentafluorobenzyl bromide (Thermo 49 Scientific) in acetone (Fisher), and 400 µL of cyclohexane (Acros Organics) in a sealed 50 autosampler vial. Samples were heated to 65 °C for 1 hour with shaking. After cooling to room 51 temperature and allowing the layers to separate, 100 μL of the cyclohexane upper phase was 1 transferred to autosampler vial containing a glass insert and sealed. Analyzed was using an GC-2 MS (Agilent 7890A GC system, Agilent 5975C MS detector) operating in negative chemical 3 ionization mode, using a DB-5MS column (30 m x 0.25 mm, 0.25, 0.25 μm; Agilent Technologies), 4 methane as the reagent gas and 1 μL split injection (1:5 split ratio). Raw peak areas for aromatic 5 analytes (tyramine and hydrocinnamic acid) were normalized to phenol-d7 internal standard and 6 lipid analytes (9,10-methylenehexadecanoic acid and 12-methyltetradecanoic acid) were 7 normalized to palmitic acid-d31 internal standard. Data analysis was performed using MassHunter 8
Quantitative Analysis software (version B.09, Agilent Technologies). 9 10
Method 2: LC triple quadrupole with reverse phase chromatography. 200 µL of extract was 11 dried using a vacuum concentrator (Genevac) and resuspended in 400 µL 50:50 methanol:water, 12
clarified by centrifugation and analyzed suing reverse phase chromatography coupled to TSQ 13
Vantage triple quadupole mass spectrometer with HESI II source. LC separation was using an 14 HSS T3 column (100 x 2.1 mm, 1.8 μm particle size, Waters) and Agilent 1260 binary pump. Additional data table S1 (separate file) 1 Table S1 List of GPCRs tested with control compounds indicated 2 Table S2 Raw screening data for GPCR agonist screen with tested positive controls 3 Table S3 Raw screening data for Orphan GPCR agonist screen 4 Table S4 List of hit filtering by receptor type 5 Table S5 a. Raw cadA BLAST analysis of HMRGD. B. cadA PFAM analysis of HMRGD 6 Table S7 Raw targeted HRMS data 7 8 9
